Drugs / ENRUPATINIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04238364 | Dec 2019 → Dec 2021 | — | Elixiron Immunotherapeutics Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06745583 | Dec 2024 → Dec 2026 expected | Alzheimer disease | Elixiron Immunotherapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Elixiron Immunotherapeutics Inc. | Results Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease elixiron.com ↗
The interim analysis demonstrated a favorable safety and tolerability profile, clear evidence of target engagement and neuroinflammation modulation as measured by translocator protein (TSPO)-PET imaging, and preliminary signals of clinical benefit in a biomarker-selected patient subgroup. |
| 2023-09-29 | Elixiron Immunotherapeutics Inc. | Regulatory EI-1071, Elixiron's drug candidate targeting microglia-induced inflammation for treating Alzheimer's disease has received the approval for a clinical trial in Taiwan elixiron.com ↗ |
| 2022-08-02 | Elixiron Immunotherapeutics Inc. | Regulatory Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis elixiron.com ↗
The U.S. FDA has granted Orphan Drug Designation to our colony stimulating factor 1 receptor inhibitor, EI-1071 for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic interstitial lung disease characterized by tissue fibrosis and progressive decline in lung function. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENRUPATINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5882296 ↗ |
| Known as | EI-1071 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06745583 ↗ |
| Modality | Small molecule | — CHEMBL5882296 ↗ |
| Route | Oral | “EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)” NCT04238364 ↗ |